Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Crucell kondigt licentieovk met ProFribix aan

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Crucell kondigt licentieovk met ProFribix aan

33 Posts
Pagina: 1 2 »» | Laatste | Omlaag ↓
  2. Grand Cru 17 december 2007 08:08
    Crucell Announces Research License Agreement with ProFibrix on STAR® Technology

    Leiden, The Netherlands, 17 December 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STAR® research license agreement with ProFibrix BV. The license with The Netherlands based ProFibrix covers the production of specific forms of human fibrinogen, a protein involved in haemostasis (blood clotting) and tissue repair. Financial details of the agreement were not disclosed.

    About STAR® Technology
    STAR® technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell's PER.C6® technology and the widely used Chinese Hamster Ovary (CHO) cell line. STAR® technology contains genetic elements, called STAR® elements, that enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells. The technology has the potential to increase production yields, thereby reducing production costs. STAR® technology was discovered by Dr. Arie Otte (Nature Biotechnology 2003 May 21, (5)) who founded Chromagenics B.V., a spin-off company of the University of Amsterdam, acquired by Crucell in March 2004.

    About Crucell
    Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad pipeline, with several products based on its unique PER.C6® production technology in development. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com

  3. [verwijderd] 17 december 2007 08:33
    Crucell sluit STAR-licentieovereenkomst met ProFibrix
    17 december 2007, 8:29 uur | FD.nl/Betten
    AMSTERDAM (FD.nl/Betten) - Crucell heeft een niet-exclusieve STAR-licentieovereenkomst voor onderzoek gesloten met het in Nederland gevestigde ProFibrix. Dat heeft het biotechnologiebedrijf maandag bekendgemaakt.

    Financiele details van de overeenkomst worden niet naar buiten gebracht. De overeenkomst is gebaseerd op de productie van specifieke vormen van menselijke fibrinogeen, een eiwit betrokken bij bloedstolling, en weefselherstel.

    Martijn Mom
    martijn@bfn.com

    (c) Het Financieele Dagblad in samenwerking met Betten Beursmedia News (contact: webred@fd.nl/ 020-5928456)
  8. sappas 17 december 2007 09:34
    quote:

    sambal schreef:

    zijn er meer mensen met een probleem bij activescreen?? . rt graag van crucell
    aand. Crucell
    Laatste Volume Tijd
    Laatste 11,99 390 09:32:29
    Verschil -0,26 -2,1224 %
    Bied 11,99 360 09:33:27
    Laat 12,01 1.778 09:33:27
    Hoogste 12,08 09:08:51
    Laagste 11,98 09:00:32
    Cum. volume --- 20.383
    Indicatieve opening ---
    Open 11,99 09:00:13
    Vorig slot 12,25 14-12-2007
    Gemiddelde dagomzet --- 415.610

    Bid Ask
    Orders Volume Bid Ask Volume Orders
    1 360 11,99 12,01 1.778 2
    1 600 11,96 12,02 2.304 4
    2 7.325 11,95 12,03 602 1
    1 3.227 11,94 12,05 925 2
    1 290 11,92 12,06 291 1

    Groetjes,

    Sappas
  15. forum rang 9 josti5 17 december 2007 10:30
    quote:

    wilb52 schreef:

    wederom wordt met zeer weinig omzet de koers , fors , onderuit gehaald.
    Charttechnisch , de zoveelste false break .
    Kortom , de koers kan naar de allerlaagste koersdoelen.
    Daar is geen redden meer aan , denk ik.
    Compliment voor de timing en de paniek opwekkende inhoud van je postings.

    Dat doe je met dit alias overigens alleen bij Crucell...
  16. gogogoo 17 december 2007 10:33
    Fibrocaps
    ProFibrix' dry powder fibrin sealant
    ProFibrix’s primary focus at the moment is on developing Fibrocaps – a new tissue sealant that stops acute and severe bleeding, after trauma injury, for example, or during surgery. Fibrocaps, a mixture of fibrinogen and thrombin, is a unique dry powder formulation that has major advantages over existing liquid tissue sealants: It is easier to prepare and use, is more stable and effective, and can be applied in various ways, including in sprays or bandages.
    The current market for surgical application alone is estimated at $ 300 - 400 million per year, and this is expected to double in the next 3-5 years. Because of its unique properties, new markets for Fibrocaps may also be found in emergency settings outside the hospital, such as in ambulances, on battlefields and in the home.
    The advantages of Fibrocaps are:
    • Ease of preparation and application (particularly on large areas).
    • Enhanced and reproducible efficacy due to improved mixing and homogeneity
    • Stored as a ready-for-use fibrinogen /thrombin blend at ambient temperatures
    • Increased viral safety profile.
    • Utility in different presentation formats (e.g. bandages)
    8,5 million euro for phase II development
    The product has been tested in animal models of liver and spleen surgery and traumatic injury. GMP manufacturing for Fibrocaps is in development and Pharse I/II testing is expected to start by the end of 2008. In march 2007, ProFibrix raised 8,5 million euro funding which is expected to allow for the complete phase II testing of Fibrocaps. Phase III testing is expected to be comple by the beginning of 2010.

    Synthocytes

    Controlling Internal Bleeding
    Synthocytes is a combination of albumin particles and fibrinogen that helps to prevent or stop internal, non-compressible bleeding in various clinical situations.
    Synthocytes is designed for treatment of patients with increased risk of internal bleeding caused by blood platelet damage, such as certain oncology and surgery patients. This application represents a € 2 billion market.
    A first prototype of the product, based on standard plasma-derived fibrinogen, has demonstrated pre-clinical efficacy in animal models (Levi et al. Nature Medicine 1999; 5: 107-111).

    BioCentury
    Hemostatic Sprinkles
    BioCentury - march 2007 (volume 15, number 14)
    ProFibrix thinks its Fibrocaps dry powder fibrin sealant may have a competetive advantage because it can be used off the shelf without rehydrating.
    www.profibrix.com/files/Biocentury%20...
    crucell.yourbb.nl/viewtopic.php?t=506
  17. [verwijderd] 17 december 2007 10:33
    Niet te filmen meer:

    Laatste 11,62 200 10:30:17
    Verschil -0,63 -5,1429 %
    Bied 11,61 74 10:30:17
    Laat 11,62 1.900 10:30:17
    Hoogste 12,08 09:08:51
    Laagste 11,61 10:14:40
    Cum. volume --- 90.815
    Indicatieve opening ---
    Open 11,99 09:00:13
    Vorig slot 12,25 14-12-2007
    Gemiddelde dagomzet --- 415.610

    Bid Ask
    Orders Volume Bid Ask Volume Orders
    1 74 11,61 11,62 1.900 2
    2 801 11,59 11,66 2.000 1
    2 1.100 11,57 11,67 1.392 2
    1 1.000 11,55 11,68 660 2
    2 965 11,54 11,70 200 1
  20. wilb52 17 december 2007 10:43
    quote:

    josti5 schreef:

    [quote=wilb52]
    wederom wordt met zeer weinig omzet de koers , fors , onderuit gehaald.
    Charttechnisch , de zoveelste false break .
    Kortom , de koers kan naar de allerlaagste koersdoelen.
    Daar is geen redden meer aan , denk ik.
    [/quote]

    Compliment voor de timing en de paniek opwekkende inhoud van je postings.

    Dat doe je met dit alias overigens alleen bij Crucell...
    Ik constateer slechts wat er gebeurt, niet meer en niet minder.
33 Posts
Pagina: 1 2 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 870,27 -0,43%
EUR/USD 1,0729 +0,29%
FTSE 100 8.078,86 +0,48%
Germany40^ 17.931,00 +0,08%
Gold spot 2.330,29 -0,07%
NY-Nasdaq Composite 15.611,76 -0,64%

Stijgers

UNILEV...
+5,85%
RENEWI
+4,68%
B&S Gr...
+2,85%
Flow T...
+2,26%
Fugro
+2,09%

Dalers

ADYEN NV
-18,43%
VIVORY...
-8,38%
WDP
-4,93%
Alfen ...
-4,39%
CM.COM
-3,66%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!